The London-based clinical research specialist MeDiNova has opened a new centre in London in order to meet increased demand for its services.
MeDiNova is a dedicated research company, with the principal aim of recruiting large numbers of patients within a short timeframe, providing high quality clinical trial data and maintaining high retention rates.
Based at Mount Vernon Hospital and Queen Mary’s Hospital in the UK, MeDiNova began its clinal research programme back in 1997.
MeDiNova works with a network of Physicians and GP’s to recruit suitable patients for clinical trials.
Over the last 18 years, the company has conducted over 300 clinical trials across a broad range of therapeutic areas in Phases I, II, III and IV.
The principal investigators at principal investigators MeDiNova, who collectively possess decades of clinical experience, are as follows:
Dr Mayura Deshpande MBBS MSc PG Dip
Dr Gowri Subramanian MB BCh BAO
Dr Baljit Chokkar MBChB
Dr Syed Abdus Saboor Aftab MD MBBS MRCP(UK) MRCP SCE(UK)
Finally, Dr Naren Savani MBBS LRCP MRCS DRCOG, who founded the company, acts as a Non Executive Director and Medical director to the company overseeing the clinical team.
The latest MeDiNova research centre will be named the East London Clinical Studies Centre, and is located at Blackburn House in Eastern Road, Romford.
According to the company, the newly opened clinical centre will enable MeDiNova to increase its intake of volunteers.
In particular, the company intends to research diabetes and respiratory problems in the foreseeable future, as well as providing regular monitoring for a diverse range of other conditions.
Diabetes can be considered of particular importance, as clinical evidence indicates that the number of people suffering with Type II diabetes in particular has increased exponentially in Britain over the last couple of decades.
MeDiNova also operates the North London Clinical Studies Centre at Mount Vernon Hospital in Northwood, and the South London Clinical Studies Centre at Queen Mary’s Hospital in Sidcup.
Kumar Muthalagappan, Chief Executive of MeDiNova, was of the opinion that the new centre will potentially allow MeDiNova to extend its reach to thousands more people across East and Greater London.
“As with our other two sites, the East London Clinical Studies Centre is strategically located in an area of high population density so we are able to deliver effective results on time and, together with our volunteers, really help make a difference in shaping advances in future treatments.”
The new centre will be staffed by 40 professional research investigators, with numerous fully professional doctors and nurses on hand.
MeDiNova has been noted for its close work with some of the world’s leading pharmaceutical companies, with CROs and biotech also part of its modus operandi.
In the London area alone, MeDiNova has scanned more than 12,000 people for osteoporosis over the past two years, using its DXA scanner, which measures bone mineral density.
Muthalagappan added: “The opening of our Romford clinic is part of our long-term plan to allow MeDiNova to continue progressing by increasing our resources and building on our achievements to date.
“Already we are able to conduct trials in no less than 45 areas. Over time our three sites will allow us to continue building on this offering and to reach out to potentially thousands more residents across a far wider catchment area who will be able to benefit from screening for a range of conditions including Osteoporosis, Diabetes and COPD.”
UK regulators have moved to assuage speculation about the birth control implant Essure.
There have been safety concerns about the product in the United States.
Nonetheless, the Medicines and Healthcare products Regulatory Agency (MHRA) has reassured UK users that the implant is indeed safe.
However, the MHRA is monitoring potential side-effects in the meantime following a furore of attention regarding Essure in the US.
The regulatory agency has advised UK women who have experienced any problems from the implant to seek advice from a general practitioner.
This sterilisation device works by blocking the fallopian tubes in order to insure that it is impossible for an egg to travel from the ovaries to the womb.
Unfortunately, there have been reports from women in the United States of injuries during usage.
Although these incidents have been relatively rare, there have been disturbing instances of the Essure device puncturing neighbouring organs, such as the bowel, at least according to US reports.
And other women utilising the product have reported allergic reactions to the nickel contained within the implant.
The equivalent of the MHRA, the Food and Drug Administration (FDA) in the United States, is currently meeting in order to assess the safety or otherwise of the product.
US media has noted that there have been more than 5,000 negative reports about the implant in the 30 years that it has been available on the market, according to the FDA.
The MHRA has declined to provide similar data, but considering that Essure is currently distributed around 1,500 women in the UK annually, the potential for serious health problems is quite obvious.
A spokeswoman for the UK regulator made it clear that the organisation has no reason to believe that the implant is unsafe for general usage.
“We currently have no information to suggest that Essure devices used in the UK are unsafe to use. We liaise regularly with the US FDA and are aware of the recent open meeting of their obstetrics and gynaecology devices panel discussing post-market experience with the Bayer Essure female sterilisation device. We continue to monitor all adverse incidents reported to us.”
Emphasising that the reports are not necessarily anything to worry about, Dr Kate Guthrie, of the Royal College of Obstetricians and Gynaecologists, stated that Essure was a good option for some women.
“It’s quite a simple procedure to do and doesn’t require surgery, unlike other sterilisation methods. But as women and clinicians, we need evidence that it is safe. I’m confident in our system of regulation. If women are getting side-effects, then we need to know about it.”
Essure is usually inserted under local anaesthetic and does not require cuts to be made in the abdomen.